Ureter Cancer - Pipeline Review, H1 2018,
provides an overview of the Ureter Cancer (Oncology) pipeline landscape.
Ureter cancer or ureteral cancer is cancer
of the ureter. Symptoms and signs of urethral cancer include bleeding from the
urethra or blood in the urine, discharge from the urethra and enlarged lymph
nodes in the groin area. Risk factors include smoking. Treatment includes
surgery, chemotherapy and radiation therapy.
Report
Highlights
Ureter Cancer - Pipeline Review, H1 2018,
provides comprehensive information on the therapeutics under development for
Ureter Cancer (Oncology), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases.
The Ureter Cancer (Oncology) pipeline guide
also reviews of key players involved in therapeutic development for Ureter
Cancer and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Phase III, Phase II and Phase I stages are
2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and
Phase I stages comprises 2 and 1 molecules, respectively.
Ureter Cancer (Oncology) pipeline guide
helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
The guide is built using data and
information sourced from Publisher’s proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ureter Cancer (Oncology)
Reasons
to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 154 pages “Ureter
Cancer - Pipeline Review, H1 2018” report covers Introduction,
Report Coverage, Ureter Cancer - Overview, Ureter Cancer - Therapeutics
Development, Ureter Cancer - Therapeutics Assessment, Ureter Cancer - Companies
Involved in Therapeutics Development, Ureter Cancer - Drug Profiles, Appendix.
This report Covered Companies - Altor BioScience Corp, Eisai Co Ltd, Exelixis
Inc, GlaxoSmithKline Plc, MedImmune LLC, Merck & Co Inc.
Please visit this link for more details: http://mrr.cm/Ujw
Find all Pharma
and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
Related
Reports;
Peanut Allergy - Pipeline Review, H1 2018 -
Visit at - http://mrr.cm/Uji
Pompe Disease - Pipeline Review, H1 2018 -
Visit at - http://mrr.cm/Uj5
No comments:
Post a Comment
Note: only a member of this blog may post a comment.